Summary of Key Information:

Nature of Filing / Announcement: Outcome of Board Meeting under Regulation 30 of SEBI Listing Regulations

Date of Board Meeting / Approval: July 8, 2026

Board Meeting Timing: Commenced at 01:00 PM IST and concluded at 02:30 PM IST

Management Change:

  • Board recommended reappointment of Dr. Ashutosh Raghuvanshi as Managing Director and Chief Executive Officer
  • Reappointment term: Two years effective from March 19, 2027
  • Current term ends on March 18, 2027
  • Subject to approval of shareholders
  • Not liable to retire by rotation

Executive Profile:

  • Dr. Ashutosh Raghuvanshi, aged about 64 years
  • Qualifications: MBBS, M.S. in General Surgery from Mahatma Gandhi Institute of Medical Sciences, Wardha; M.Ch. in Cardiac Surgery from Bombay Hospital Institute of Medical Sciences
  • Current position: Managing Director & Chief Executive Officer of Fortis Healthcare Limited
  • Experience: Over 38 years in healthcare sector
  • Previous experience: Over 18 years with Narayana Health, holding leadership positions including Vice Chairman, Managing Director and Group Chief Executive Officer
  • Industry engagement: Closely engaged with CII, FICCI, and NATHEALTH; served as President of NATHEALTH from 2023 to 2024
  • Awards: Received numerous national and international awards for contributions to healthcare industry

Regulatory Disclosures:

  • Dr. Raghuvanshi is not related to any other directors of the Company
  • Dr. Raghuvanshi is not debarred from accessing capital markets
  • Dr. Raghuvanshi is not restrained from holding any position/office of director pursuant to SEBI or any other authority order

Filing Details:

  • Filed pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015
  • Reference to SEBI Master Circular O/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026
  • Signed by Satyendra Chauhan, Company Secretary & Compliance Officer (M. No. A14783)

Key Financial Highlights: Not Specified

Standalone Results: Not Specified

Consolidated Results: Not Specified

Segment-wise Performance: Not Specified

Corporate Actions: Not Specified

Regulatory Disclosures (Additional): Not Specified

Other Significant Information: Not Specified